Overview

A Study of SA-001 to Treat Pancreatic Exocrine Insufficiency

Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study is to verify the efficacy of 3.0 g/day of SA-001 in patients with pancreatic exocrine insufficiency caused by chronic pancreatitis in the non-compensatory stage or by pancreatectomy as compared with placebo under a double-blind design using the change in a coefficient of fat absorption as a primary endpoint.
Phase:
Phase 3
Details
Lead Sponsor:
Abbott